{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rivastigmine",
    "query": {
      "intervention": "Rivastigmine"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 34,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rivastigmine&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-04T21:49:42.693Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02670161",
      "title": "Quality Improvement and Practice Based Research in Neurology Using the EMR",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Brain Tumors",
        "Epilepsy",
        "Migraine",
        "Mild Cognitive Impairment",
        "Concussion",
        "Multiple Sclerosis",
        "Neuropathy",
        "Parkinson's",
        "Restless Legs Syndrome",
        "Stroke"
      ],
      "interventions": [
        {
          "name": "Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Endeavor Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 3300,
      "start_date": "2016-05",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2025-08-24",
      "last_synced_at": "2026-09-04T21:49:42.693Z",
      "location_count": 1,
      "location_summary": "Evanston, Illinois",
      "locations": [
        {
          "city": "Evanston",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02670161"
    },
    {
      "nct_id": "NCT00988117",
      "title": "The Effects of the Rivastigmine Patch on Parkinson's Disease With Memory and/or Thinking Problems",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Parkinsons Disease With Dementia",
        "Parkinsons Disease With Mild to Moderate Memory and/or Thinking Problems"
      ],
      "interventions": [
        {
          "name": "Rivastigmine Patch 9.5 cm2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2010-04",
      "completion_date": "2011-04",
      "has_results": true,
      "last_update_posted_date": "2014-02-26",
      "last_synced_at": "2026-09-04T21:49:42.693Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00988117"
    },
    {
      "nct_id": "NCT00000174",
      "title": "Investigation Into Delay to Diagnosis of Alzheimer's Disease With Exelon (InDDEx)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer Disease",
        "Cognition Disorders"
      ],
      "interventions": [
        {
          "name": "Rivastigmine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "55 Years to 85 Years"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-09-04T21:49:42.693Z",
      "location_count": 15,
      "location_summary": "Peoria, Arizona • Orange, California • Denver, Colorado + 12 more",
      "locations": [
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000174"
    },
    {
      "nct_id": "NCT00948766",
      "title": "Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Rivastigmine 4.6 mg/24 h (5 cm^2)",
          "type": "DRUG"
        },
        {
          "name": "Rivastigmine 9.5 mg/24 h (10 cm^2)",
          "type": "DRUG"
        },
        {
          "name": "Rivastigmine 13.3 mg/24 h (15 cm^2)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 716,
      "start_date": "2009-07",
      "completion_date": "2012-06",
      "has_results": true,
      "last_update_posted_date": "2013-08-28",
      "last_synced_at": "2026-09-04T21:49:42.693Z",
      "location_count": 93,
      "location_summary": "Tempe, Arizona • Tucson, Arizona • Conway, Arkansas + 84 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Conway",
          "state": "Arkansas"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00948766"
    },
    {
      "nct_id": "NCT03915626",
      "title": "Effect of Heat on Rivastigmine TDS Products",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Bioavailability"
      ],
      "interventions": [
        {
          "name": "Rivastigmine (RLD) transdermal patch",
          "type": "DRUG"
        },
        {
          "name": "Rivastigmine (generic) transdermal patch",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 7,
      "start_date": "2019-10-04",
      "completion_date": "2021-05-04",
      "has_results": true,
      "last_update_posted_date": "2022-04-04",
      "last_synced_at": "2026-09-04T21:49:42.693Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03915626"
    },
    {
      "nct_id": "NCT01602198",
      "title": "Study of Exelon Transdermal Patch in Amnestic Mild Cognitive Impairment Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Mild Cognitive Disorder",
        "Mild Cognitive Impairment"
      ],
      "interventions": [
        {
          "name": "Exelon [rivastigmine] transdermal patch",
          "type": "DRUG"
        },
        {
          "name": "Placebo transdermal patch",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Cleveland Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "55 Years to 85 Years"
      },
      "enrollment_count": 1,
      "start_date": "2011-06",
      "completion_date": "2013-01",
      "has_results": true,
      "last_update_posted_date": "2017-02-28",
      "last_synced_at": "2026-09-04T21:49:42.693Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01602198"
    },
    {
      "nct_id": "NCT00099216",
      "title": "Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Vascular Dementia"
      ],
      "interventions": [
        {
          "name": "Rivastigmine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 708,
      "start_date": "2001-08",
      "completion_date": "2005-11",
      "has_results": false,
      "last_update_posted_date": "2011-11-17",
      "last_synced_at": "2026-09-04T21:49:42.693Z",
      "location_count": 17,
      "location_summary": "Irvine, California • San Francisco, California • Boynton Beach, Florida + 14 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Boynton Beach",
          "state": "Florida"
        },
        {
          "city": "Miami Beach",
          "state": "Florida"
        },
        {
          "city": "Port Charlotte",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00099216"
    },
    {
      "nct_id": "NCT03840837",
      "title": "Cholinergic Neurotransmission in Mobility and Cognition in Parkinson Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Parkinson Disease",
        "Parkinson Disease Dementia"
      ],
      "interventions": [
        {
          "name": "Rivastigmine transdermal patch",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2019-05-02",
      "completion_date": "2020-04-01",
      "has_results": false,
      "last_update_posted_date": "2023-12-20",
      "last_synced_at": "2026-09-04T21:49:42.693Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03840837"
    },
    {
      "nct_id": "NCT00551161",
      "title": "Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "memantine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwell Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2007-08",
      "completion_date": "2011-12",
      "has_results": true,
      "last_update_posted_date": "2014-01-28",
      "last_synced_at": "2026-09-04T21:49:42.693Z",
      "location_count": 1,
      "location_summary": "Manhasset, New York",
      "locations": [
        {
          "city": "Manhasset",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00551161"
    },
    {
      "nct_id": "NCT01073319",
      "title": "Rivastigmine as a Treatment for Methamphetamine Dependence",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Methamphetamine Dependence",
        "Substance Abuse",
        "Methamphetamine Abuse"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Rivastigmine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 17,
      "start_date": "2009-07",
      "completion_date": "2010-07",
      "has_results": false,
      "last_update_posted_date": "2012-07-27",
      "last_synced_at": "2026-09-04T21:49:42.693Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01073319"
    }
  ]
}